Washington: US President Donald Trump announced to impose 100/% tariffs on imports of branded and patented pharmaceutical drugs from October 1^st, 2025.

Trump’s decision will impact on India’s pharmaceuticals sector, one of the most dependent domestic industries on trade with America. Starting October 1st, 2025, we will be imposing a 100% tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America, he added on Truth Social media.

“IS BUILDING” will be defined as, breaking ground and or under construction. There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started. Thank you for your attention to this matter, he added in his social media account Truth.

Although the latest American tariffs appear to mainly target branded and patented drugs a segment dominated by multinational giants uncertainty looms over whether complex generics and specialty medicines from India would also be under the scanner.

American consumers depend on low-cost generics manufactured in India. Higher tariffs would lead to price hikes, inflation and drug shortages in the country. Meanwhile, Indian companies, operating on thin margins in the US generics space, may struggle to absorb costs and end up passing them on to US consumers or insurers.